Project Grant R34MH124968
- This $2.9 million Defense Health Agency project grant funds research on suicide prevention among military personnel and veterans. The grant supports a multi-site randomized clinical trial through September 2026 to evaluate the efficacy of Written Exposure Therapy for Suicide Prevention compared to treatment as usual. Researchers at Boston University and partner institutions University of Colorado Denver and University of Texas Health Science Center San Antonio aim to reduce suicidal thoughts and...
- Federal Grant Award Summary Boston University Medical Campus received a $191,972 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded on September 8, 2025, with a completion date of August 31, 2030. The grant supports a pilot randomized controlled trial (RCT) examining an adapted Cognitive Processing Therapy (CPT) intervention designed to address posttraumatic stress disorder (PTSD) and co-occurring lived...
- Federal Grant Award Summary Boston University Medical Campus received a $567,000 Project Grant from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), awarded September 8, 2025, with a completion date of September 7, 2028. The award funds research to augment Cognitive Processing Therapy (CPT)—a first-line evidence-based psychotherapy for Post-Traumatic Stress Disorder (PTSD)—with a peer-led support intervention designed to enhance mental...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate an adapted version of Written Exposure Therapy (WET) for treating posttraumatic stress disorder (PTSD) among individuals with opioid use disorder (OUD) in residential substance use disorder (SUD) treatment settings. The $798,605 award will fund a multi-site study to create and test the adapted "Written Exposure in...
- This federal Project Grant award of $2,993,024.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of lethal means safety counseling for service members and civilians with post-traumatic stress disorder (PTSD). The study, titled "FIREARM SAFETY IN PTSD (FASP): A RANDOMIZED CONTROLLED TRIAL OF LETHAL MEANS SAFETY COUNSELING AMONG SERVICE MEMBERS AND CIVILIANS WITH PTSD", will be conducted by...
- This federal Project Grant award of $2,398,281.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program aims to increase access to evidence-based PTSD treatment for military service members and veterans through Behavioral Health Technician-delivered Written Exposure Therapy (WET). The primary awardee, Palo Alto Veterans Institute for Research (Pavir), will oversee the overall project objectives, which include providing WET training to...
- This $2,763,615 federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a randomized controlled trial of brief prolonged exposure therapy for injured individuals admitted to a Level I trauma center. The goal is to evaluate the effectiveness of this approach in preventing post-traumatic stress disorder (PTSD) in this patient population. The 4-year study is being conducted by the Baylor Research Institute, a non-profit...
- This Project Grant award of $2,384,097, provided by the Defense Health Agency through the Military Medical Research and Development (CFDA 12.420) federal grant program, is funding a hybrid experimental clinical trial to determine the optimal sequencing of interventions to maximize the effectiveness of PTSD treatment. The primary awardee, The University of Texas Health Science Center at San Antonio, will conduct this research with a planned completion date of August 2028. The project involves two...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $6,964,861.00 to The University of Texas Health Science Center at San Antonio to conduct a multi-year longitudinal study focused on military psychological health. The study has five specific aims: Conduct a prospective, longitudinal follow-up of 3,360 previous clinical trial participants treated for PTSD, sleep disorders, or chronic pain. Conduct a...
- Federal Project Grant Award Summary Adaptive Interventions for Co-Occurring Opioid Use Disorder and Post-Traumatic Stress Disorder The RAND Corporation received a $408,679 project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025 through August 31, 2027. This research initiative develops and tests scalable, equitable treatment strategies for patients with co-occurring opioid use disorder (OUD)...
A PILOT EFFECTIVENESS TRIAL OF COGNITIVE PROCESSING THERAPY AUGMENTED WITH SUICIDE RISK MANAGEMENT FOR INDIVIDUALS WITH COMORBID PTSD AND BPD - 7. PROJECT SUMMARY THIS PROJECT IS A PILOT EFFECTIVENESS TRIAL DESIGNED TO EVALUATE COGNITIVE PROCESSING THERAPY AUGMENTED WITH A SUICIDE RISK MANAGEMENT PROTOCOL (CPT+SRM), AS A VIABLE TREATMENT FOR INDIVIDUALS WITH COMORBID POSTTRAUMATIC STRESS DISORDER (PTSD) AND BORDERLINE PERSONALITY DISORDER (BPD). PTSD IS A SIGNIFICANT PUBLIC HEALTH PROBLEM ASSOCIATED WITH DEBILITATING OUTCOMES SUCH AS SUICIDE, EMPLOYMENT DIFFICULTIES, AND FAMILY DISRUPTION. THESE OUTCOMES ARE FURTHER COMPOUNDED WHEN PTSD IS COMORBID WITH BPD. THE COMORBIDITY OF PTSD AND BPD (PTSD-BPD) IS AS HIGH AS 58% AND IS ASSOCIATED WITH EVEN GREATER FUNCTIONAL IMPAIRMENT (E.G., SUICIDE RISK) AND, SUBSEQUENTLY, HEALTHCARE UTILIZATION THAN EITHER DISORDER ALONE. DESPITE THE CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITH PTSD-BPD, FEW TREATMENTS EXIST FOR THIS POPULATION AND EMERGING TREATMENTS ARE LENGTHY, INTENSIVE, RESOURCE-HEAVY, AND DIFFICULT TO SUSTAIN IN REAL-WORLD COMMUNITY SETTINGS. USING AN EXPERIMENTAL THERAPEUTICS APPROACH, THIS PROPOSAL EVALUATES CPT+SRM AS A PARSIMONIOUS, INTEGRATIVE INTERVENTION THAT TARGETS KEY MECHANISMS SHARED ACROSS PTSD AND BPD- I.E., EMOTIONAL REACTIVITY AND COGNITIVE DYSFUNCTION. THE STANFORD OUTPATIENT GENERAL ADULT PSYCHOSOCIAL TREATMENT CLINIC WILL SERVE AS THE TREATMENT SITE AND STUDY THERAPISTS WILL BE COMMUNITY CLINICIANS WITH PART-TIME APPOINTMENTS AT THE CLINIC. PHASE 1 OF THIS INVESTIGATION WILL CONSIST OF AN INITIAL CASE SERIES (N=5) IN WHICH WE WILL DEVELOP AND ITERATE THE MANUAL, DEVELOP FIDELITY MEASURES, AND STREAMLINE OUR RESEARCH PROCEDURES. THE FINALIZED TREATMENT MANUAL WILL THEN BE TESTED IN PHASE 2, A RANDOMIZED- CONTROLLED TRIAL (N=28) COMPARING 12 INDIVIDUAL SESSIONS/6 WEEKS OF CPT+SRM (N=14) VERSUS 6 WEEKS OF SRM ONLY (N=14). PARTICIPANTS WILL BE ASSESSED AT PRE-TREATMENT, MID-TREATMENT/3- WEEKS, POST-TREATMENT/6-WEEKS, AND 3-MONTH POST-TREATMENT FOLLOW-UP. AIM 1 WILL BE TO EVALUATE THE FEASIBILITY, ACCEPTABILITY, AND SAFETY OF CPT+SRM. AIM 2 WILL BE TO PRELIMINARILY EVALUATE THE EFFECTIVENESS OF CPT+SRM. AIM 3 WILL BE TO EXAMINE THE RELATIONSHIP BETWEEN CHANGE IN OUR PUTATIVE TARGET MECHANISMS (MEASURED USING SELF-REPORT, BEHAVIORAL, AND PHYSIOLOGICAL INDICATORS), AND PRIMARY CLINICAL OUTCOMES (I.E., PTSD AND BPD SEVERITY). THE LONG-TERM OBJECTIVE OF THIS RESEARCH IS TO CONDUCT A SUBSEQUENT LARGE-SCALE INTERVENTION TRIAL THROUGH AN R01 MECHANISM AND ULTIMATELY ENHANCE SERVICE DELIVERY AND ACCESSIBILITY OF CARE FOR THIS CLINICALLY COMPLEX AND ECONOMICALLY BURDENSOME POPULATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/28/26 | ||
| Not listed | $16.9k | 7/22/24 | ||
| Not listed | $151.8k | 2/1/24 | ||
| Not listed | $151.8k | 2/1/24 | ||
| Not listed | $279.4k | 2/3/23 |